Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

1(13%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_4

13%

Ph phase_2

38%

Ph phase_3

25%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Terminated(1)

Detailed Status

Completed6

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (25.0%)

Phase 23 (37.5%)

Phase 32 (25.0%)

Phase 41 (12.5%)

Trials by Status

terminated113%

active_not_recruiting113%

completed675%

Recent Activity

1 active trials

Showing 5 of 8

active_not_recruitingphase_2

Early Infant HIV Treatment in Botswana

NCT02369406

completedphase_2

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636

completedphase_3

Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)

NCT01307124

completedphase_1

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

NCT02256826

terminatedphase_4

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir

NCT01031849

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02369406Phase 2

Early Infant HIV Treatment in Botswana

Active Not Recruiting

NCT00116636Phase 2

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

Completed

NCT01307124Phase 3

Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)

Completed

NCT02256826Phase 1

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Completed

NCT01031849Phase 4

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir

Terminated

NCT00085943Phase 3

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Completed

NCT00766818Phase 1

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet

Completed

NCT00052117Phase 2

Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8